文献速递乳腺癌

监测血清DNA甲基化作为转移性乳腺癌缓解与生存的早期独立标志物:TBCRC 005前瞻性生物标志物研究

Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study.
PubMed 文献 · J Clin Oncol · 2016-11-21

TBCRC 005多中心前瞻性研究纳入141例转移性乳腺癌女性,用cMethDNA检测10基因血清甲基化并生成累积甲基化指数(CMI)。第4周高CMI较低CMI的PFS(2.1 vs 5.8个月)和OS(12.3 vs 21.7个月)显著更短,且高CMI独立关联更差PFS(HR 1.79)和OS(HR 1.75)。

要点

  • 第4周高CMI者PFS 2.1个月、OS 12.3个月,低CMI者PFS 5.8个月、OS 21.7个月。
  • 第4周高 vs 低CMI独立关联更差PFS(HR 1.79;95%CI 1.23-2.60;P=.002)和OS(HR 1.75;95%CI 1.21-2.54;P=.003)。
  • 第4周CMI在存在循环肿瘤细胞时仍是PFS的强预测因子(P=.004)。

核心结论

  • 该基因面板甲基化是转移性乳腺癌生存结局的强预测因子,可能在风险分层和疾病监测中有临床用处。

研究设计与样本

  • 多中心前瞻性研究TBCRC 005,纳入141例女性转移性乳腺癌患者,在基线、第4周和首次再分期时检测血清样本中10个基因的甲基化,每个样本设复孔。
  • 基于所测10个基因中的6个生成累积甲基化指数(CMI),甲基化cut point以最大化log-rank统计量选取,并用交叉验证获得无偏点估计。
  • 用逻辑回归或Cox比例风险模型检验CMI与无进展生存(PFS)、总生存(OS)及首次再分期时疾病状态之间的关联,并评估CMI在预测生存结局中的附加价值,与循环肿瘤细胞(CellSearch)比较。

主要发现

  • 高CMI者中位PFS 2.1个月、中位OS 12.3个月,低CMI者中位PFS 5.8个月、中位OS 21.7个月,高CMI者PFS和OS均显著更短。
  • 多变量模型中,第4周高 vs 低CMI独立关联更差PFS(HR 1.79;95%CI 1.23-2.60;P=.002)和更差OS(HR 1.75;95%CI 1.21-2.54;P=.003)。
  • CMI从基线到第4周升高与更差PFS(P<.001)及首次再分期时疾病进展(P<.001)相关。
  • 第4周CMI在存在循环肿瘤细胞时仍是PFS的强预测因子(P=.004)。

临床怎么用

  • 作者认为该基因面板甲基化是转移性乳腺癌生存结局的强预测因子,可能在风险分层和疾病监测中有临床用处。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Epigenetic alterations measured in blood may help guide breast cancer treatment. The multisite prospective study TBCRC 005 was conducted to examine the ability of a novel panel of cell-free DNA methylation markers to predict survival outcomes in metastatic breast cancer (MBC) using a new quantitative multiplex assay (cMethDNA). Patients and Methods Ten genes were tested in duplicate serum samples from 141 women at baseline, at week 4, and at first restaging. A cumulative methylation index (CMI) was generated on the basis of six of the 10 genes tested. Methylation cut points were selected to maximize the log-rank statistic, and cross-validation was used to obtain unbiased point estimates. Logistic regression or Cox proportional hazard models were used to test associations between the CMI and progression-free survival (PFS), overall survival (OS), and disease status at first restaging. The added value of the CMI in predicting survival outcomes was evaluated and compared with circulating tumor cells (CellSearch). Results Median PFS and OS were significantly shorter in women with a high CMI (PFS, 2.1 months; OS, 12.3 months) versus a low CMI (PFS, 5.8 months; OS, 21.7 months). In multivariable models, among women with MBC, a high versus low CMI at week 4 was independently associated with worse PFS (hazard ratio, 1.79; 95% CI, 1.23 to 2.60; P = .002) and OS (hazard ratio, 1.75; 95% CI, 1.21 to 2.54; P = .003). An increase in the CMI from baseline to week 4 was associated with worse PFS ( P < .001) and progressive disease at first restaging ( P < .001). Week 4 CMI was a strong predictor of PFS, even in the presence of circulating tumor cells ( P = .004). Conclusion Methylation of this gene panel is a strong predictor of survival outcomes in MBC and may have clinical usefulness in risk stratification and disease monitoring.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Visvanathan K, Fackler MS, Zhang Z, et al. Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study. J Clin Oncol. 2016. PMID: 27870562. doi:10.1200/JCO.2015.66.2080

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。